Abstract
Bone formation is the key for successful dental treatments including periodontal tissue regeneration osseointegration of implant placement in which new alveolar bone formation is mandatory. Parathyroid hormone (PTH) is a peptide hormone containing 84 amino acids. Accumulated results show that intermittent PTH administration increases bone mass. Accordingly, recombinant N-terminal fragment of human PTH (1-34) , Teriparatide, is used for the treatments of osteoporosis worldwide. It is, therefore, expected that PTH has the potential to be a new therapeutic intervention for oral diseases that require increased bone remodeling and new bone formation.
MeSH terms
-
Adaptor Proteins, Signal Transducing
-
Animals
-
Bisphosphonate-Associated Osteonecrosis of the Jaw / drug therapy
-
Bone Density Conservation Agents / pharmacology
-
Bone Density Conservation Agents / therapeutic use*
-
Bone Morphogenetic Proteins / physiology
-
Bone Remodeling / drug effects
-
Dental Implants
-
Genetic Markers / physiology
-
Humans
-
Insulin-Like Growth Factor I / physiology
-
Osseointegration / drug effects
-
Osteogenesis / drug effects
-
Parathyroid Hormone / chemistry
-
Parathyroid Hormone / pharmacology
-
Parathyroid Hormone / physiology
-
Parathyroid Hormone / therapeutic use*
-
Stimulation, Chemical
-
Stomatognathic Diseases / drug therapy*
-
Teriparatide / pharmacology
-
Teriparatide / therapeutic use*
-
Wnt Signaling Pathway / physiology
Substances
-
Adaptor Proteins, Signal Transducing
-
Bone Density Conservation Agents
-
Bone Morphogenetic Proteins
-
Dental Implants
-
Genetic Markers
-
Parathyroid Hormone
-
SOST protein, human
-
Teriparatide
-
Insulin-Like Growth Factor I